Compile Data Set for Download or QSAR
Report error Found 402 Enz. Inhib. hit(s) with all data for entry = 1494
TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Agios Pharmaceuticals

US Patent
LigandPNGBDBM326468(US9662327, Compound 165)
Affinity DataIC50: 500nMAssay Description:Assays were conducted in a volume of 76 μl assay buffer (150 mM NaCl, 10 mM MgCl2, 20 mM Tris pH 7.5, 0.03% bovine serum albumin) as follows in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2019
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Agios Pharmaceuticals

US Patent
LigandPNGBDBM326474(US9662327, Compound 171)
Affinity DataIC50: 500nMAssay Description:Assays were conducted in a volume of 76 μl assay buffer (150 mM NaCl, 10 mM MgCl2, 20 mM Tris pH 7.5, 0.03% bovine serum albumin) as follows in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2019
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Agios Pharmaceuticals

US Patent
LigandPNGBDBM326479(US9662327, Compound 176)
Affinity DataIC50: 500nMAssay Description:Assays were conducted in a volume of 76 μl assay buffer (150 mM NaCl, 10 mM MgCl2, 20 mM Tris pH 7.5, 0.03% bovine serum albumin) as follows in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2019
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Agios Pharmaceuticals

US Patent
LigandPNGBDBM326483(US9662327, Compound 180)
Affinity DataIC50: 500nMAssay Description:Assays were conducted in a volume of 76 μl assay buffer (150 mM NaCl, 10 mM MgCl2, 20 mM Tris pH 7.5, 0.03% bovine serum albumin) as follows in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2019
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Agios Pharmaceuticals

US Patent
LigandPNGBDBM326484(US9662327, Compound 181)
Affinity DataIC50: 500nMAssay Description:Assays were conducted in a volume of 76 μl assay buffer (150 mM NaCl, 10 mM MgCl2, 20 mM Tris pH 7.5, 0.03% bovine serum albumin) as follows in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2019
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Agios Pharmaceuticals

US Patent
LigandPNGBDBM326497(US9662327, Compound 194)
Affinity DataIC50: 500nMAssay Description:Assays were conducted in a volume of 76 μl assay buffer (150 mM NaCl, 10 mM MgCl2, 20 mM Tris pH 7.5, 0.03% bovine serum albumin) as follows in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2019
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Agios Pharmaceuticals

US Patent
LigandPNGBDBM326498(US9662327, Compound 195)
Affinity DataIC50: 500nMAssay Description:Assays were conducted in a volume of 76 μl assay buffer (150 mM NaCl, 10 mM MgCl2, 20 mM Tris pH 7.5, 0.03% bovine serum albumin) as follows in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2019
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Agios Pharmaceuticals

US Patent
LigandPNGBDBM326508(US9662327, Compound 205)
Affinity DataIC50: 500nMAssay Description:Assays were conducted in a volume of 76 μl assay buffer (150 mM NaCl, 10 mM MgCl2, 20 mM Tris pH 7.5, 0.03% bovine serum albumin) as follows in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2019
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Agios Pharmaceuticals

US Patent
LigandPNGBDBM326509(US9662327, Compound 206)
Affinity DataIC50: 500nMAssay Description:Assays were conducted in a volume of 76 μl assay buffer (150 mM NaCl, 10 mM MgCl2, 20 mM Tris pH 7.5, 0.03% bovine serum albumin) as follows in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2019
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Agios Pharmaceuticals

US Patent
LigandPNGBDBM326510(US9662327, Compound 207)
Affinity DataIC50: 500nMAssay Description:Assays were conducted in a volume of 76 μl assay buffer (150 mM NaCl, 10 mM MgCl2, 20 mM Tris pH 7.5, 0.03% bovine serum albumin) as follows in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2019
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Agios Pharmaceuticals

US Patent
LigandPNGBDBM326514(US9662327, Compound 211)
Affinity DataIC50: 500nMAssay Description:Assays were conducted in a volume of 76 μl assay buffer (150 mM NaCl, 10 mM MgCl2, 20 mM Tris pH 7.5, 0.03% bovine serum albumin) as follows in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2019
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Agios Pharmaceuticals

US Patent
LigandPNGBDBM326533(US9662327, Compound 230)
Affinity DataIC50: 500nMAssay Description:Assays were conducted in a volume of 76 μl assay buffer (150 mM NaCl, 10 mM MgCl2, 20 mM Tris pH 7.5, 0.03% bovine serum albumin) as follows in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2019
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Agios Pharmaceuticals

US Patent
LigandPNGBDBM326461(US9662327, Compound 158 | US9662327, Compound 231)
Affinity DataIC50: 500nMAssay Description:Assays were conducted in a volume of 76 μl assay buffer (150 mM NaCl, 10 mM MgCl2, 20 mM Tris pH 7.5, 0.03% bovine serum albumin) as follows in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2019
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Agios Pharmaceuticals

US Patent
LigandPNGBDBM326538(US9662327, Compound 235)
Affinity DataIC50: 500nMAssay Description:Assays were conducted in a volume of 76 μl assay buffer (150 mM NaCl, 10 mM MgCl2, 20 mM Tris pH 7.5, 0.03% bovine serum albumin) as follows in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2019
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Agios Pharmaceuticals

US Patent
LigandPNGBDBM326539(US9662327, Compound 236)
Affinity DataIC50: 500nMAssay Description:Assays were conducted in a volume of 76 μl assay buffer (150 mM NaCl, 10 mM MgCl2, 20 mM Tris pH 7.5, 0.03% bovine serum albumin) as follows in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2019
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Agios Pharmaceuticals

US Patent
LigandPNGBDBM326540(US9662327, Compound 237)
Affinity DataIC50: 500nMAssay Description:Assays were conducted in a volume of 76 μl assay buffer (150 mM NaCl, 10 mM MgCl2, 20 mM Tris pH 7.5, 0.03% bovine serum albumin) as follows in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2019
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Agios Pharmaceuticals

US Patent
LigandPNGBDBM326568(US9662327, Compound 265)
Affinity DataIC50: 500nMAssay Description:Assays were conducted in a volume of 76 μl assay buffer (150 mM NaCl, 10 mM MgCl2, 20 mM Tris pH 7.5, 0.03% bovine serum albumin) as follows in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2019
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Agios Pharmaceuticals

US Patent
LigandPNGBDBM326572(US9662327, Compound 269)
Affinity DataIC50: 500nMAssay Description:Assays were conducted in a volume of 76 μl assay buffer (150 mM NaCl, 10 mM MgCl2, 20 mM Tris pH 7.5, 0.03% bovine serum albumin) as follows in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2019
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Agios Pharmaceuticals

US Patent
LigandPNGBDBM326573(US9662327, Compound 270)
Affinity DataIC50: 500nMAssay Description:Assays were conducted in a volume of 76 μl assay buffer (150 mM NaCl, 10 mM MgCl2, 20 mM Tris pH 7.5, 0.03% bovine serum albumin) as follows in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2019
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Agios Pharmaceuticals

US Patent
LigandPNGBDBM326591(US9662327, Compound 288)
Affinity DataIC50: 500nMAssay Description:Assays were conducted in a volume of 76 μl assay buffer (150 mM NaCl, 10 mM MgCl2, 20 mM Tris pH 7.5, 0.03% bovine serum albumin) as follows in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2019
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Agios Pharmaceuticals

US Patent
LigandPNGBDBM326592(US9662327, Compound 289)
Affinity DataIC50: 500nMAssay Description:Assays were conducted in a volume of 76 μl assay buffer (150 mM NaCl, 10 mM MgCl2, 20 mM Tris pH 7.5, 0.03% bovine serum albumin) as follows in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2019
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Agios Pharmaceuticals

US Patent
LigandPNGBDBM326600(US9662327, Compound 297)
Affinity DataIC50: 500nMAssay Description:Assays were conducted in a volume of 76 μl assay buffer (150 mM NaCl, 10 mM MgCl2, 20 mM Tris pH 7.5, 0.03% bovine serum albumin) as follows in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2019
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Agios Pharmaceuticals

US Patent
LigandPNGBDBM326607(US9662327, Compound 304)
Affinity DataIC50: 500nMAssay Description:Assays were conducted in a volume of 76 μl assay buffer (150 mM NaCl, 10 mM MgCl2, 20 mM Tris pH 7.5, 0.03% bovine serum albumin) as follows in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2019
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Agios Pharmaceuticals

US Patent
LigandPNGBDBM326610(US9662327, Compound 307)
Affinity DataIC50: 500nMAssay Description:Assays were conducted in a volume of 76 μl assay buffer (150 mM NaCl, 10 mM MgCl2, 20 mM Tris pH 7.5, 0.03% bovine serum albumin) as follows in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2019
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Agios Pharmaceuticals

US Patent
LigandPNGBDBM326620(US9662327, Compound 317)
Affinity DataIC50: 500nMAssay Description:Assays were conducted in a volume of 76 μl assay buffer (150 mM NaCl, 10 mM MgCl2, 20 mM Tris pH 7.5, 0.03% bovine serum albumin) as follows in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2019
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Agios Pharmaceuticals

US Patent
LigandPNGBDBM326755(US9662327, Compound 340)
Affinity DataIC50: 500nMAssay Description:Assays were conducted in a volume of 76 μl assay buffer (150 mM NaCl, 10 mM MgCl2, 20 mM Tris pH 7.5, 0.03% bovine serum albumin) as follows in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2019
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Agios Pharmaceuticals

US Patent
LigandPNGBDBM326759(US9662327, Compound 344)
Affinity DataIC50: 500nMAssay Description:Assays were conducted in a volume of 76 μl assay buffer (150 mM NaCl, 10 mM MgCl2, 20 mM Tris pH 7.5, 0.03% bovine serum albumin) as follows in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2019
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Agios Pharmaceuticals

US Patent
LigandPNGBDBM326760(US9662327, Compound 345)
Affinity DataIC50: 500nMAssay Description:Assays were conducted in a volume of 76 μl assay buffer (150 mM NaCl, 10 mM MgCl2, 20 mM Tris pH 7.5, 0.03% bovine serum albumin) as follows in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2019
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Agios Pharmaceuticals

US Patent
LigandPNGBDBM326761(US9662327, Compound 346)
Affinity DataIC50: 500nMAssay Description:Assays were conducted in a volume of 76 μl assay buffer (150 mM NaCl, 10 mM MgCl2, 20 mM Tris pH 7.5, 0.03% bovine serum albumin) as follows in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2019
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Agios Pharmaceuticals

US Patent
LigandPNGBDBM326762(US9662327, Compound 347)
Affinity DataIC50: 500nMAssay Description:Assays were conducted in a volume of 76 μl assay buffer (150 mM NaCl, 10 mM MgCl2, 20 mM Tris pH 7.5, 0.03% bovine serum albumin) as follows in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2019
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Agios Pharmaceuticals

US Patent
LigandPNGBDBM326769(US9662327, Compound 354)
Affinity DataIC50: 500nMAssay Description:Assays were conducted in a volume of 76 μl assay buffer (150 mM NaCl, 10 mM MgCl2, 20 mM Tris pH 7.5, 0.03% bovine serum albumin) as follows in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2019
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Agios Pharmaceuticals

US Patent
LigandPNGBDBM326781(US9662327, Compound 366)
Affinity DataIC50: 500nMAssay Description:Assays were conducted in a volume of 76 μl assay buffer (150 mM NaCl, 10 mM MgCl2, 20 mM Tris pH 7.5, 0.03% bovine serum albumin) as follows in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2019
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Agios Pharmaceuticals

US Patent
LigandPNGBDBM326791(US9662327, Compound 376)
Affinity DataIC50: 500nMAssay Description:Assays were conducted in a volume of 76 μl assay buffer (150 mM NaCl, 10 mM MgCl2, 20 mM Tris pH 7.5, 0.03% bovine serum albumin) as follows in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2019
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Agios Pharmaceuticals

US Patent
LigandPNGBDBM326797(US9662327, Compound 382)
Affinity DataIC50: 500nMAssay Description:Assays were conducted in a volume of 76 μl assay buffer (150 mM NaCl, 10 mM MgCl2, 20 mM Tris pH 7.5, 0.03% bovine serum albumin) as follows in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2019
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Agios Pharmaceuticals

US Patent
LigandPNGBDBM326798(US9662327, Compound 383 | US9662327, Compound 437 ...)
Affinity DataIC50: 500nMAssay Description:Assays were conducted in a volume of 76 μl assay buffer (150 mM NaCl, 10 mM MgCl2, 20 mM Tris pH 7.5, 0.03% bovine serum albumin) as follows in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2019
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Agios Pharmaceuticals

US Patent
LigandPNGBDBM326807(US9662327, Compound 392)
Affinity DataIC50: 500nMAssay Description:Assays were conducted in a volume of 76 μl assay buffer (150 mM NaCl, 10 mM MgCl2, 20 mM Tris pH 7.5, 0.03% bovine serum albumin) as follows in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2019
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Agios Pharmaceuticals

US Patent
LigandPNGBDBM326810(US9662327, Compound 395)
Affinity DataIC50: 500nMAssay Description:Assays were conducted in a volume of 76 μl assay buffer (150 mM NaCl, 10 mM MgCl2, 20 mM Tris pH 7.5, 0.03% bovine serum albumin) as follows in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2019
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Agios Pharmaceuticals

US Patent
LigandPNGBDBM326816(US9662327, Compound 401)
Affinity DataIC50: 500nMAssay Description:Assays were conducted in a volume of 76 μl assay buffer (150 mM NaCl, 10 mM MgCl2, 20 mM Tris pH 7.5, 0.03% bovine serum albumin) as follows in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2019
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Agios Pharmaceuticals

US Patent
LigandPNGBDBM326824(US9662327, Compound 409)
Affinity DataIC50: 500nMAssay Description:Assays were conducted in a volume of 76 μl assay buffer (150 mM NaCl, 10 mM MgCl2, 20 mM Tris pH 7.5, 0.03% bovine serum albumin) as follows in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2019
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Agios Pharmaceuticals

US Patent
LigandPNGBDBM326827(US9662327, Compound 450 | US9662327, Compound 412)
Affinity DataIC50: 500nMAssay Description:Assays were conducted in a volume of 76 μl assay buffer (150 mM NaCl, 10 mM MgCl2, 20 mM Tris pH 7.5, 0.03% bovine serum albumin) as follows in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2019
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Agios Pharmaceuticals

US Patent
LigandPNGBDBM326828(US9662327, Compound 413)
Affinity DataIC50: 500nMAssay Description:Assays were conducted in a volume of 76 μl assay buffer (150 mM NaCl, 10 mM MgCl2, 20 mM Tris pH 7.5, 0.03% bovine serum albumin) as follows in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2019
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Agios Pharmaceuticals

US Patent
LigandPNGBDBM326837(US9662327, Compound 477 | US9662327, Compound 423)
Affinity DataIC50: 500nMAssay Description:Assays were conducted in a volume of 76 μl assay buffer (150 mM NaCl, 10 mM MgCl2, 20 mM Tris pH 7.5, 0.03% bovine serum albumin) as follows in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2019
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Agios Pharmaceuticals

US Patent
LigandPNGBDBM326838(US9662327, Compound 424)
Affinity DataIC50: 500nMAssay Description:Assays were conducted in a volume of 76 μl assay buffer (150 mM NaCl, 10 mM MgCl2, 20 mM Tris pH 7.5, 0.03% bovine serum albumin) as follows in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2019
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Agios Pharmaceuticals

US Patent
LigandPNGBDBM326839(US9662327, Compound 425)
Affinity DataIC50: 500nMAssay Description:Assays were conducted in a volume of 76 μl assay buffer (150 mM NaCl, 10 mM MgCl2, 20 mM Tris pH 7.5, 0.03% bovine serum albumin) as follows in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2019
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Agios Pharmaceuticals

US Patent
LigandPNGBDBM326840(US9662327, Compound 426)
Affinity DataIC50: 500nMAssay Description:Assays were conducted in a volume of 76 μl assay buffer (150 mM NaCl, 10 mM MgCl2, 20 mM Tris pH 7.5, 0.03% bovine serum albumin) as follows in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2019
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Agios Pharmaceuticals

US Patent
LigandPNGBDBM326842(US9662327, Compound 428)
Affinity DataIC50: 500nMAssay Description:Assays were conducted in a volume of 76 μl assay buffer (150 mM NaCl, 10 mM MgCl2, 20 mM Tris pH 7.5, 0.03% bovine serum albumin) as follows in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2019
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Agios Pharmaceuticals

US Patent
LigandPNGBDBM326843(US9662327, Compound 429)
Affinity DataIC50: 500nMAssay Description:Assays were conducted in a volume of 76 μl assay buffer (150 mM NaCl, 10 mM MgCl2, 20 mM Tris pH 7.5, 0.03% bovine serum albumin) as follows in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2019
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Agios Pharmaceuticals

US Patent
LigandPNGBDBM326844(US9662327, Compound 430)
Affinity DataIC50: 500nMAssay Description:Assays were conducted in a volume of 76 μl assay buffer (150 mM NaCl, 10 mM MgCl2, 20 mM Tris pH 7.5, 0.03% bovine serum albumin) as follows in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2019
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Agios Pharmaceuticals

US Patent
LigandPNGBDBM326847(US9662327, Compound 433)
Affinity DataIC50: 500nMAssay Description:Assays were conducted in a volume of 76 μl assay buffer (150 mM NaCl, 10 mM MgCl2, 20 mM Tris pH 7.5, 0.03% bovine serum albumin) as follows in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2019
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132H](Human)
Agios Pharmaceuticals

US Patent
LigandPNGBDBM326848(US9662327, Compound 434)
Affinity DataIC50: 500nMAssay Description:Assays were conducted in a volume of 76 μl assay buffer (150 mM NaCl, 10 mM MgCl2, 20 mM Tris pH 7.5, 0.03% bovine serum albumin) as follows in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2019
Entry Details
Go to US Patent

Displayed 1 to 50 (of 402 total ) | Next | Last >>
Jump to: